Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristina Rowe

Nurse Practitioner, Psychiatric/Mental Health Ironton, OH Nurse Practitioner

NPI 1528236262 CMS profile 10420569

1408 Campbell Dr, Ironton, OH 45638

Open in the dashboard

General payments

$252,697

742 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristina Rowe of Ironton, OH is reported in the CMS Open Payments database as having received $252,697 across 742 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,879 126
2024 General $45,237 123
2023 General $51,848 155
2022 General $58,176 183
2021 General $27,557 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Rowe
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Kristina Rowe were reported at $69,879. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Kristina Rowe Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $27,557 $166 $54–$482 $132
2022 $58,176 $195 $66–$559 $149
2023 $51,848 $233 $82–$673 $160
2024 $45,237 $236 $84–$688 $164
2025 $69,879 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $177,535 191 payments
  2. AbbVie, Inc. $68,974 220 payments
  3. Allergan Inc. $1,650 2 payments
  4. Lundbeck LLC $760 80 payments
  5. Sunovion Pharmaceuticals Inc. $669 71 payments
  6. Otsuka America Pharmaceutical, Inc. $521 39 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $459 28 payments
  8. Axsome Therapeutics, Inc. $351 15 payments
  9. Janssen Pharmaceuticals, Inc $329 17 payments
  10. Vanda Pharmaceuticals Inc. $300 10 payments
  11. Other $1,149 69 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201,407 95 payments
  2. Consulting Fee $21,188 5 payments
  3. Travel and Lodging $19,014 101 payments
  4. Food and Beverage $11,088 541 payments
Products named General payments · program years 2021–2025
  1. INGREZZA Neuropsychiatry $159,615 173 payments
  2. VRAYLAR Neuroscience $47,122 161 payments
  3. VRAYLAR Neuroscience $20,921 53 payments
  4. INGREZZA Neurology $17,920 18 payments
  5. LATUDA $669 71 payments
  6. REXULTI Psychiatry $633 54 payments
  7. REXULTI Psychiatry $499 38 payments
  8. TRINTELLIX $459 28 payments
  9. Auvelity $351 15 payments
  10. CAPLYTA $263 18 payments
  11. Other $2,889 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,132

Median for Nurse Practitioner: 389

Drug cost

$571,150

Median for Nurse Practitioner: $21,885

Branded share of claims

28.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 29 $235,585
Vraylar Cariprazine Hcl Brand 105 $154,317
Rexulti Brexpiprazole Brand 32 $58,249
Auvelity Dextromethorphan Hbr/Bupropion Brand 24 $36,551
Trintellix Vortioxetine Hydrobromide Brand 20 $23,385
Caplyta Lumateperone Tosylate Brand 11 $17,986
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 59 $5,051
Aripiprazole Generic 17 $4,311
Lurasidone Hcl Generic 28 $3,265
Quetiapine Fumarate Generic 98 $2,566

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$303

Medicare's payments for the services billed

Medicare patients

22

Average age 59

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Depression 55%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $27,335
$27,335 29 —
VRAYLAR
  • AbbVie, Inc. $17,272
$17,272 105 —
REXULTI
  • Lundbeck LLC $161
  • Otsuka America Pharmaceutical, Inc. $75
$235 32 —
Auvelity
  • Axsome Therapeutics, Inc. $157
$157 24 —
FANAPT
  • Vanda Pharmaceuticals Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

742 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record